{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Drug Slows Progression in Refractory HER2+ Breast Cancer
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Purpose of Activity
To provide information on the results of the HER2CLIMB trial.Learning Objectives
After completing this continuing education activity you will be able to:
- Identify the indication for and potential toxicities from tucatinib.
- Evaluate results from the HER2CLIMB trial related to progression-free survival and overall survival with the use of tucatinib.
Disclosures
The author(s), faculty, staff, and planners, including spouses/partners (if any), in any position to control the content of this activity, have disclosed that they have no financial relationships with, or financial interests in, any commercial companies relevant to this educational activity.
Price:
$12.95
Credits:
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT0420
Published: April 2020
Expires: 12/31/2026
Sources:
Oncology Times
Required Passing Score: 8/10 (80%)
Specialties:
Oncology,
Women's Health